Allergen immunotherapy: A practice parameter second update
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthm...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2007-09, Vol.120 (3), p.S25-S85 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S85 |
|---|---|
| container_issue | 3 |
| container_start_page | S25 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 120 |
| creator | Cox, Linda, MD Li, James T., MD Nelson, Harold, MD Lockey, Richard, MD |
| description | These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the “Allergen immunotherapy: a practice parameter second update.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion. |
| doi_str_mv | 10.1016/j.jaci.2007.06.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21013977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S009167490701202X</els_id><sourcerecordid>20949608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c604t-65131251cf2d9ce50ed61a8c4ea666d3ec318ec7a25adceda6fdc07958484eff3</originalsourceid><addsrcrecordid>eNqFkluL1TAQgIso7nH1D_ggBdG31knaJM0iwmHxBgs-qOBbiJOppva2SSucf2_KOXBgH9ynMPDNZGa-ybLnDEoGTL7pys6iLzmAKkGWwPSDbMdAq0I2XDzMdgCaFVLV-iJ7EmMHKa4a_Ti7YEpJAarZZVf7vqfwi8bcD8M6TstvCnY-XOX7fA4WF4-UzzbYgRYKeSScRpevs7MLPc0etbaP9Oz0XmbfP7z_dv2puPny8fP1_qZACfVSSMEqxgXDljuNJICcZLbBmqyU0lWEFWsIleXCOiRnZesQlBZN3dTUttVl9vpYdw7T7UpxMYOPSH1vR5rWaHhaRqWVuh8EXWsJzb0g00Kw1FwCX94Bu2kNY5rWMAGiAi51nSh-pDBMMQZqzRz8YMPBMDCbKdOZzZTZTBmQJplKSS9OpdefA7lzyklNAl6dABvR9m2wI_p45jRowfnGvT1ylBz89RRMRE9j2qQPhItxk_9_H-_upGPvR59-_EMHiud5TeQGzNftpraTAgWMA_9R_QMcQsT8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505302694</pqid></control><display><type>article</type><title>Allergen immunotherapy: A practice parameter second update</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB Electronic Journals Library</source><creator>Cox, Linda, MD ; Li, James T., MD ; Nelson, Harold, MD ; Lockey, Richard, MD</creator><contributor>Lockey, Richard ; Cox, Linda</contributor><creatorcontrib>Cox, Linda, MD ; Li, James T., MD ; Nelson, Harold, MD ; Lockey, Richard, MD ; American College of Allergy, Asthma and Immunology ; American Academy of Allergy, Asthma and Immunology ; Joint Task Force on Practice Parameters ; Joint Council of Allergy, Asthma and Immunology ; Lockey, Richard ; Cox, Linda</creatorcontrib><description>These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the “Allergen immunotherapy: a practice parameter second update.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2007.06.019</identifier><identifier>PMID: 17765078</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Allergens - administration & dosage ; Allergens - therapeutic use ; Allergens - toxicity ; Allergies ; Allergy and Immunology ; Biological and medical sciences ; Colleges & universities ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Hospitals ; Humans ; Hypersensitivity, Immediate - therapy ; Immunopathology ; Immunotherapy - standards ; Immunotherapy - trends ; Medical sciences ; Medical treatment ; Patient Selection ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Time Factors</subject><ispartof>Journal of allergy and clinical immunology, 2007-09, Vol.120 (3), p.S25-S85</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2007 American Academy of Allergy, Asthma & Immunology</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Elsevier Limited Sep 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c604t-65131251cf2d9ce50ed61a8c4ea666d3ec318ec7a25adceda6fdc07958484eff3</citedby><cites>FETCH-LOGICAL-c604t-65131251cf2d9ce50ed61a8c4ea666d3ec318ec7a25adceda6fdc07958484eff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S009167490701202X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19095228$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17765078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lockey, Richard</contributor><contributor>Cox, Linda</contributor><creatorcontrib>Cox, Linda, MD</creatorcontrib><creatorcontrib>Li, James T., MD</creatorcontrib><creatorcontrib>Nelson, Harold, MD</creatorcontrib><creatorcontrib>Lockey, Richard, MD</creatorcontrib><creatorcontrib>American College of Allergy, Asthma and Immunology</creatorcontrib><creatorcontrib>American Academy of Allergy, Asthma and Immunology</creatorcontrib><creatorcontrib>Joint Task Force on Practice Parameters</creatorcontrib><creatorcontrib>Joint Council of Allergy, Asthma and Immunology</creatorcontrib><title>Allergen immunotherapy: A practice parameter second update</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the “Allergen immunotherapy: a practice parameter second update.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.</description><subject>Allergens - administration & dosage</subject><subject>Allergens - therapeutic use</subject><subject>Allergens - toxicity</subject><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Biological and medical sciences</subject><subject>Colleges & universities</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Hypersensitivity, Immediate - therapy</subject><subject>Immunopathology</subject><subject>Immunotherapy - standards</subject><subject>Immunotherapy - trends</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Patient Selection</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Time Factors</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkluL1TAQgIso7nH1D_ggBdG31knaJM0iwmHxBgs-qOBbiJOppva2SSucf2_KOXBgH9ynMPDNZGa-ybLnDEoGTL7pys6iLzmAKkGWwPSDbMdAq0I2XDzMdgCaFVLV-iJ7EmMHKa4a_Ti7YEpJAarZZVf7vqfwi8bcD8M6TstvCnY-XOX7fA4WF4-UzzbYgRYKeSScRpevs7MLPc0etbaP9Oz0XmbfP7z_dv2puPny8fP1_qZACfVSSMEqxgXDljuNJICcZLbBmqyU0lWEFWsIleXCOiRnZesQlBZN3dTUttVl9vpYdw7T7UpxMYOPSH1vR5rWaHhaRqWVuh8EXWsJzb0g00Kw1FwCX94Bu2kNY5rWMAGiAi51nSh-pDBMMQZqzRz8YMPBMDCbKdOZzZTZTBmQJplKSS9OpdefA7lzyklNAl6dABvR9m2wI_p45jRowfnGvT1ylBz89RRMRE9j2qQPhItxk_9_H-_upGPvR59-_EMHiud5TeQGzNftpraTAgWMA_9R_QMcQsT8</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Cox, Linda, MD</creator><creator>Li, James T., MD</creator><creator>Nelson, Harold, MD</creator><creator>Lockey, Richard, MD</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20070901</creationdate><title>Allergen immunotherapy: A practice parameter second update</title><author>Cox, Linda, MD ; Li, James T., MD ; Nelson, Harold, MD ; Lockey, Richard, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c604t-65131251cf2d9ce50ed61a8c4ea666d3ec318ec7a25adceda6fdc07958484eff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Allergens - administration & dosage</topic><topic>Allergens - therapeutic use</topic><topic>Allergens - toxicity</topic><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Biological and medical sciences</topic><topic>Colleges & universities</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Hypersensitivity, Immediate - therapy</topic><topic>Immunopathology</topic><topic>Immunotherapy - standards</topic><topic>Immunotherapy - trends</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Patient Selection</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cox, Linda, MD</creatorcontrib><creatorcontrib>Li, James T., MD</creatorcontrib><creatorcontrib>Nelson, Harold, MD</creatorcontrib><creatorcontrib>Lockey, Richard, MD</creatorcontrib><creatorcontrib>American College of Allergy, Asthma and Immunology</creatorcontrib><creatorcontrib>American Academy of Allergy, Asthma and Immunology</creatorcontrib><creatorcontrib>Joint Task Force on Practice Parameters</creatorcontrib><creatorcontrib>Joint Council of Allergy, Asthma and Immunology</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cox, Linda, MD</au><au>Li, James T., MD</au><au>Nelson, Harold, MD</au><au>Lockey, Richard, MD</au><au>Lockey, Richard</au><au>Cox, Linda</au><aucorp>American College of Allergy, Asthma and Immunology</aucorp><aucorp>American Academy of Allergy, Asthma and Immunology</aucorp><aucorp>Joint Task Force on Practice Parameters</aucorp><aucorp>Joint Council of Allergy, Asthma and Immunology</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allergen immunotherapy: A practice parameter second update</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>120</volume><issue>3</issue><spage>S25</spage><epage>S85</epage><pages>S25-S85</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the “Allergen immunotherapy: a practice parameter second update.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>17765078</pmid><doi>10.1016/j.jaci.2007.06.019</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2007-09, Vol.120 (3), p.S25-S85 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21013977 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB Electronic Journals Library |
| subjects | Allergens - administration & dosage Allergens - therapeutic use Allergens - toxicity Allergies Allergy and Immunology Biological and medical sciences Colleges & universities Fundamental and applied biological sciences. Psychology Fundamental immunology Hospitals Humans Hypersensitivity, Immediate - therapy Immunopathology Immunotherapy - standards Immunotherapy - trends Medical sciences Medical treatment Patient Selection Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Time Factors |
| title | Allergen immunotherapy: A practice parameter second update |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A26%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allergen%20immunotherapy:%20A%20practice%20parameter%20second%20update&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Cox,%20Linda,%20MD&rft.aucorp=American%20College%20of%20Allergy,%20Asthma%20and%20Immunology&rft.date=2007-09-01&rft.volume=120&rft.issue=3&rft.spage=S25&rft.epage=S85&rft.pages=S25-S85&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2007.06.019&rft_dat=%3Cproquest_cross%3E20949608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505302694&rft_id=info:pmid/17765078&rft_els_id=1_s2_0_S009167490701202X&rfr_iscdi=true |